By Fineline Cube Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its Category 1 chemical drug HRS-7058 capsules have received Breakthrough Therapy Designation (BTD) from China’s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) for the treatment of locally advanced or metastatic pancreatic cancer with KRAS G12C mutations in patients who have failed at least one prior line of systemic therapy.
Regulatory Milestone
| Component | Detail |
|---|---|
| Agency | CDE/NMPA (China) |
| Designation | Breakthrough Therapy Designation (BTD) |
| Drug | HRS-7058 capsules – Category 1 chemical drug |
| Indication | Locally advanced/metastatic pancreatic cancer with KRAS G12C mutations |
| Patient Population | Post-first-line systemic therapy failure |
| Drug Class | Novel, potent, selective small-molecule covalent KRAS G12C inhibitor |
| Announcement Date | 14 Jul 2026 |
Drug Profile & Clinical Data
HRS-7058 – Targeted KRAS G12C Inhibitor
- Molecule Type: Small-molecule covalent inhibitor
- Target: KRAS G12C mutation (specifically targets the G12C variant)
- Classification: Category 1 chemical drug (China’s highest innovation tier)
- Broader Indication: Advanced solid tumors harboring KRAS G12C mutations
- Development Stage: Phase I completed, BTD granted based on clinical data
Phase I Clinical Results
- Efficacy: Demonstrated clinically meaningful activity in later-line pancreatic cancer treatment
- Safety Profile: Generally manageable with standard supportive care
- Patient Population: Heavily pre-treated advanced pancreatic cancer patients
- Significance: Addresses critical unmet need in one of oncology’s most challenging tumor types
Pancreatic cancer represents one of the most lethal malignancies, with a five-year survival rate of approximately 12%. The KRAS G12C mutation, while less common in pancreatic cancer (1-2% of cases) compared to lung cancer (13%), represents a validated therapeutic target with significant clinical implications for this molecularly-defined subset.
Market Context & Competitive Landscape
| Aspect | Details |
|---|---|
| KRAS Target Validation | Previously considered “undruggable,” KRAS G12C inhibitors represent breakthrough class following sotorasib (Lumakras) and adagrasib (Krazati) approvals |
| Pancreatic Cancer Market | Limited treatment options post-first-line; median overall survival of 6-9 months in refractory setting |
| Competitive Position | HRS-7058 would be among first KRAS G12C inhibitors specifically evaluated in pancreatic cancer population |
| Global Potential | Success in China could support international development given unmet need globally |
| Addressable Population | Estimated 1,500-2,000 KRAS G12C-mutant pancreatic cancer patients annually in China |
Strategic Implications
- Accelerated Development Pathway: BTD provides expedited review, intensive guidance, and potential priority approval pathway
- Commercial Opportunity: Premium pricing potential for targeted therapy addressing high-unmet-need indication
- Pipeline Validation: Demonstrates Hengrui’s capability to develop world-class targeted oncology therapeutics
- Investor Confidence: Reinforces Hengrui’s position as China’s leading innovative pharmaceutical company
- Global Ambitions: Success could position HRS-7058 for international partnerships or direct global development
The KRAS G12C inhibitor market is projected to reach $3.5 billion globally by 2030, with pancreatic cancer representing a high-value niche indication due to limited alternatives and poor prognosis.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory pathways, clinical development, and commercial potential for HRS-7058. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption rates.-Fineline Info & Tech